Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.46 |
| ▸ | AKT2 | P31751 | 7/20 | 0.45 |
| ▸ | CKS1B | P61024 | 4/20 | 0.39 |
| ▸ | SKP1 | P63208 | 4/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17885229 | 0.96 | AKT1 (0.49) | AKT1AKT2CKS1BSKP1SKP2 | |
| SCHEMBL17885126 | 0.91 | AKT1 (0.40) | AKT1AKT2CKS1BSKP1SKP2 | |
| SCHEMBL17885235 | 0.91 | AKT1 (0.40) | AKT1AKT2CKS1BSKP1SKP2 | |
| SCHEMBL17885272 | 0.91 | AKT1 (0.40) | AKT1AKT2CKS1BSKP1SKP2 | |
| SCHEMBL19829506 | 0.90 | AKT1 (0.39) | AKT1AKT2CKS1BSKP1SKP2 | |
| SCHEMBL17885240 | 0.88 | AKT1 (0.44) | AKT1AKT2KITDYRK1A | |
| SCHEMBL17872549 | 0.85 | AKT1 (0.51) | AKT1AKT2TACR3DYRK1A | |
| SCHEMBL17885279 | 0.85 | AKT1 (0.44) | AKT1AKT2CKS1BSKP1SKP2 | |
| SCHEMBL17885125 | 0.84 | AKT1 (0.41) | AKT1AKT2CNR1CNR2KIT | |
| SCHEMBL17885160 | 0.82 | AKT1 (0.40) | AKT1AKT2CNR1CNR2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| WO-2016102672-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | AKT1 2288/4885AKT2 1340/4885CKS1B 1509/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | AKT1 2193/4885AKT2 1292/4885CKS1B 1415/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | AKT1 2193/4885AKT2 1292/4885CKS1B 1415/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | AKT1 2288/4885AKT2 1340/4885CKS1B 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.